Saturday 17 October 2026 Export ILMN’s income statement to Excel — free account

Illumina, Inc.

Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024. In the quarter to June 2026, revenue grew 9.44%, EPS fell 8.05%, free cash flow fell 18.3% and total debt was flat, each against the same quarter a year earlier. Member of the S&P 500; operating cash flow growth for three consecutive years; insiders bought in the last twelve months.

262.03 5.90 −2.20%

Follow ILMN

Alert me

Market cap: $40.5B
P/E: 48.4×
Fwd P/E: 34.7×
Dividend yield: —
F-score: 8/9
Altman Z: 4.39
Beneish M: −2.51
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total buys 0.08

Total sells 592.86

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	1	—	—	—	—	—	—	—	—
Sell	—	2	—	2	—	—	5	3	1	4	1	—

Insider Ownership 0.34%

Capital & Financial Ratios $m

Market Cap 40,460.00

Revenue 4,493.00

Net Income 824.00

Free Cash Flow 931.00

Net Debt 323.00

Current Ratio 1.80

Debt/Equity 0.53

P/E ratio 48.43

Fwd P/E 34.70

P/S ratio 8.81

P/B ratio 13.94

Past 5Y EPS Growth 4.14%

This Y EPS Growth 10.65%

Next Y EPS Growth 13.84%

Next Y revenue growth 6.47%

Next 5Y EPS Growth 12.98%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 47.20%

10-year low 10-year high

P/S against its own 10 years 43.90%

10-year low 10-year high

P/B against its own 10 years 96.31%

10-year low 10-year high

EV/Sales against its own 10 years 45.04%

10-year low 10-year high

EV/FCF against its own 10 years 31.08%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,054	1,220	1,633	1,168
Receivables	734	735	854	764
Inventory	587	547	564	629
Other	—	—	—	—
	2,609	2,746	3,289	2,834

	2023	2024	2025	Q'26
Payables	245	221	240	230
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1,570	1,547	1,585	1,578

Compound Annual Growth %

	10y	5y	3y
Sales	6.94%	6.04%	(1.78%)
Cash Flow	3.22%	(0.02%)	40.15%
Earnings	6.29%	5.32%	0.00%
Book Value	3.95%	(10.32%)	(25.55%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1,091	1,159	—	—	—
’25	1,041	1,059	1,084	1,159	4,343
’24	1,076	1,112	1,080	1,104	4,372
’23	1,087	1,176	1,119	1,122	4,504
’22	1,223	1,162	1,115	1,084	4,584
’21	1,093	1,126	1,108	1,199	4,526
’20	859	633	794	953	3,239

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	289	201	—	—	—
’25	240	234	284	321	1,079
’24	77	80	316	364	837
’23	10	105	139	224	478
’22	172	125	(52)	147	392
’21	282	253	(272)	282	545
’20	281	240	153	406	1,080

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	251	161	—	—	—
’25	201	197	253	266	931
’24	41	49	284	335	709
’23	(43)	58	94	172	282
’22	111	54	(298)	59	(74)
’21	240	209	(324)	212	337
’20	241	201	105	344	891

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	0.87	1.35	—	—	—
’25	0.82	1.49	0.98	2.16	5.45
’24	(0.79)	(12.48)	4.42	1.17	(7.69)
’23	0.02	(1.48)	(4.77)	(1.11)	(7.34)
’22	0.55	(3.40)	(24.26)	(0.89)	(28.00)
’21	1.00	1.26	2.08	0.71	5.04
’20	1.17	0.32	1.21	1.75	4.45

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	116.12	124.67	201.86	256.13	191.42	331.74	168.73	86.58	97.36	68.70	Analyst estimates 2026–2028 Powerpack
	High	183.12	224.44	362.46	370.39	393.19	540.63	416.34	232.05	156.66	153.06
People
People	Employees	5,500	6,200	7,300	7,700	7,850	9,150	10,260	9,300	9,030	8,650
	Revenue/emp, $m	0.44	0.44	0.46	0.46	0.41	0.49	0.45	0.48	0.48	0.50
Income, $m
Income, $m	Revenue	2,398	2,752	3,333	3,543	3,239	4,526	4,584	4,504	4,372	4,343
	Gross margin, %	69.47	66.35	69.01	69.63	68.01	69.69	64.83	60.92	65.44	66.08
	EBT	561	1,043	894	1,118	856	884	(4,336)	(1,117)	(1,179)	1,086
	EBT margin, %	23.39	37.90	26.82	31.56	26.43	19.53	(94.59)	(24.80)	(26.97)	25.01
	Net income	428	678	782	990	656	762	(4,404)	(1,161)	(1,223)	850
	Depreciation	171	186	220	234	227	283	394	432	354	270
Per share, $
Per share, $	Revenue	16.31	18.85	22.67	24.10	22.03	30.17	29.20	28.51	27.50	28.02
	Earnings	3.09	4.96	5.63	6.81	4.48	5.07	(28.00)	(7.34)	(7.69)	5.47
	Cash flow	5.30	5.99	7.77	7.15	7.35	3.63	2.50	3.03	5.26	6.96
	Capex	(1.84)	(2.14)	(2.01)	(1.42)	(1.29)	(1.39)	(2.97)	(1.24)	(0.80)	(0.95)
	Free cash flow	3.46	3.86	5.76	5.73	6.06	2.25	(0.47)	1.78	4.46	6.01
	Book value	15.44	18.83	26.16	31.38	31.93	71.60	42.03	36.36	14.92	17.57
	Shares, m	147	146	147	147	147	150	157	158	159	155
Valuation, ×
Valuation, ×	P/E	40.50	43.59	51.91	47.39	80.34	72.71	0.00	0.00	0.00	23.93
	P/S	7.82	11.56	12.87	13.39	16.33	12.27	6.69	4.70	4.86	4.68
	P/B	8.26	11.57	11.15	10.28	11.27	5.17	4.65	3.68	8.95	7.47
	EV/Sales	7.61	11.22	12.41	12.76	15.63	12.45	6.68	4.90	5.03	4.76
	EV/FCF	35.95	55.91	49.67	54.53	57.65	173.94	(402.84)	78.55	31.12	22.57
Cash, $m
Cash, $m	Operating cash flow	779	875	1,142	1,051	1,080	545	392	478	837	1,079
	Capex	(271)	(312)	(296)	(209)	(189)	(208)	(466)	(196)	(128)	(148)
	Free cash flow	508	563	846	842	891	337	(74)	282	709	931
Balance, $m
Balance, $m	Working capital	1,613	2,234	2,686	3,786	3,239	1,620	788	1,039	1,199	1,704
	Total debt	1,058	1,192	1,997	1,186	1,184	1,695	1,487	1,489	1,490	1,490
	Net debt	(501)	(953)	(1,515)	(2,228)	(2,288)	356	(550)	435	270	(143)
	Shareholders’ equity	2,270	2,749	3,845	4,613	4,694	10,740	6,599	5,745	2,373	2,723
Returns, %
Returns, %	ROA	11.62	15.22	13.52	14.04	8.80	6.68	(32.07)	(10.38)	(14.90)	13.13
	ROIC	20.74	21.09	23.69	25.81	15.07	(0.69)	(43.18)	(10.81)	(19.70)	19.55
	ROE	22.48	28.93	25.05	23.69	14.10	9.87	(50.80)	(18.81)	(30.13)	33.36

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
NTRA Natera, Inc.	$58.4B	— (loss-making)	— (loss-making)	+37.71% (above 0%: growing)	n/m	−173.96% (below 0%: shrinking)	64.46%	(10.07%)	Compare
A Agilent Technologies, Inc.	$49.5B	34.0×	26.3×	+8.06% (above 0%: growing)	+8.47% (above 0%: growing)	+69.50% (above 0%: growing)	55.48%	23.64%	Compare
IQV IQVIA Holdings Inc.	$44.6B	32.8×	22.3×	+8.74% (above 0%: growing)	−0.65% (below 0%: shrinking)	+23.29% (above 0%: growing)	32.85%	11.58%	Compare
WAT Waters Corporation	$43.6B	109×	44.3×	+113.36% (above 0%: growing)	n/m	+750.00% (above 0%: growing)	44.62%	(5.23%)	Compare
IDXX IDEXX Laboratories, Inc.	$43.1B	39.1×	38.3×	+9.66% (above 0%: growing)	+17.21% (above 0%: growing)	+111.44% (above 0%: growing)	64.04%	34.98%	Compare
ILMN Illumina, Inc.	$40.5B	48.4×	34.7×	+9.44% (above 0%: growing)	−8.05% (below 0%: shrinking)	−18.27% (below 0%: shrinking)	66.44%	21.14%
MTD Mettler-Toledo International, Inc.	$32.8B	36.4×	25.5×	+4.48% (above 0%: growing)	+18.30% (above 0%: growing)	+33.01% (above 0%: growing)	63.29%	30.61%	Compare
DGX Quest Diagnostics Incorporated	$26.4B	24.6×	20.8×	+10.21% (above 0%: growing)	+14.74% (above 0%: growing)	+5.28% (above 0%: growing)	33.75%	15.08%	Compare
LH Labcorp Holdings Inc.	$26.4B	26.2×	19.0×	+5.78% (above 0%: growing)	+28.42% (above 0%: growing)	−42.01% (below 0%: shrinking)	29.80%	12.10%	Compare
Median of peers	$43.4B	34.0×	25.5×	+9.20%	+15.98%	+28.15%	50.05%	13.59%

All 52 Diagnostics & Research stocks →

Illumina, Inc. (ILMN) key facts

Concern: Illumina, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.3 billion, down 0.66% from fiscal 2024.
Illumina, Inc. (ILMN) is a Diagnostics & Research company in the Healthcare sector, listed on Nasdaq.
Net income was $850.0 million, or $5.47 per share (basic), a net margin of 19.6%.
As of October 16, 2026, ILMN traded at $262.03, a market capitalization of $40.5 billion.
At that price the stock trades at 48.4× trailing-twelve-month earnings and 8.8× sales; its P/E is higher than 47% of its own readings over the past ten years.
Return on equity was 33.4% and debt-to-equity 0.53.
Its Piotroski F-score is 8 out of 9 and its Altman Z-score is 4.39 (safe zone) for fiscal 2025.